Thyroid function in patients with type 1 diabetes mellitus and chronic kidney disease receiving renal replacement therapy

Authors

  • A.G. Sazonоva Belarusian State Medical University, Minsk, Republic of Belarus Republican Center for Medical Rehabilitation and Balneotherapy, Minsk, Republic of Belarus
  • T.V. Mokhort Belarusian State Medical University, Minsk, Republic of Belarus http://orcid.org/0000-0002-5040-3460
  • N.V. Karlovich Belarusian State Medical University, Minsk, Republic of Belarus Republican Center for Medical Rehabilitation and Balneotherapy, Minsk, Republic of Belarus
  • V.S. Snapkov Republican Center for Medical Rehabilitation and Balneotherapy, Minsk, Republic of Belarus
  • O.E. Valovik Republican Center for Medical Rehabilitation and Balneotherapy, Minsk, Republic of Belarus
  • O.V. Ilinchik City Clinical Hospital 1, Minsk, Republic of Belarus

DOI:

https://doi.org/10.22141/2224-0721.16.1.2020.199122

Keywords:

type 1 diabetes mellitus, thyroid gland, renal replacement therapy, chronic kidney disease

Abstract

Background. Impaired thyroid function is a common endocrine pathology among patients with chronic kidney disease (CKD), including those receiving renal replacement therapy. The results of the Third National Health and Nutrition Examination Survey demonstrated that the proportion of patients with hypothyroidism rises to 23 % in progressive impaired renal function. The purpose was to study the effect of renal replacement therapy on the thyroid function in patients with type 1 diabetes mellitus and CKD. Materials and methods. We assessed thyroid function in 155 diabetic patients with end-stage CKD in a cross-sectional study. When assessing the functional status of the thyroid gland, the calculated indicators were used: the peripheral conversion index and the integral thyroid index. Peripheral conversion index was calculated as the ratio of free T4 to free T3. Results. No significant differences were found between the groups of patients receiving renal replacement therapy and patients with type 1 diabetes mellitus with and without comorbid CKD in terms of total T4 and T3, thyroglobulin, thyroglobulin antibodies and thyroid peroxidase antibodies. Significantly lower rates of free T4 and free T3 were noted with a maximum decrease when receiving renal replacement therapy. A significant decrease in the levels of thyroid-stimulating hormone receptor antibodies confirms the absence of influence of autoimmunity on the origin of thyroid disorders in patients with CKD receiving renal replacement therapy. No relationship was found between the thyroid hormones and HbA1c in type 1 diabetes mellitus patients receiving renal replacement therapy, as well as between the duration of CKD and renal replacement therapy and thyroid profile. Conclusions. These changes predetermine the need to assess serum levels of free fractions of peripheral thyroid hormones, as well as hormonal studies immediately after the hemodialysis procedure.

References

Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17(1):45–63. doi:10.1210/edrv-17-1-45.

Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009;160(4):503–515. doi:10.1530/EJE-08-0837.

Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005;67(3):1047–1052. doi:10.1111/j.1523-1755.2005.00169.x.

Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1296–1300. doi:10.2215/CJN.00800208.

Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499. doi:10.1210/jcem.87.2.8182.

Brüngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Am J Physiol. 1997;272(5 Pt 2):F648–F653. doi:10.1152/ajprenal.1997.272.5.F648.

Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004;19(5):1190–1197. doi:10.1093/ndt/gfh096.

Rhee CM, Brent GA, Kovesdy CP, et al. Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015;30(5):724–737. doi:10.1093/ndt/gfu024.

Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–1049. doi:10.1161/CIRCULATIONAHA.112.096024.

Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270–278. doi:10.7326/0003-4819-132-4-200002150-00004.

US Renal Data System. USRDS 2014 Annual Data Report: Volume 2 – End-Stage Renal Disease (ESRD) in the United States. Bethesda, MD; US Renal Data System; 2014. Available from: https://www.usrds.org/2014/view/.

You AS, Sim JJ, Kovesdy CP, et al. Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrol Dial Transplant. 2019;34(12):2095–2104. doi:10.1093/ndt/gfy289.

Shin DH, Lee MJ, Kim SJ, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2012;97(8):2732–2740. doi:10.1210/jc.2012-1663.

Liu P, Liu R, Chen X, et al. Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study. Curr Med Res Opin. 2015;31(12):2233–2240. doi:10.1185/03007995.2015.1094044.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.

Kandor VI, ed. Synthesis, secretion and metabolism of thyroid hormones: Clinical endocrinology. SPb, Russian Federation: Piter; 2002. 122-127 pp. (in Russian).

Rebrova O. Statistical analysis of medical data. Application software package Statistica. Moskow: Media Sphere; 2002. 312 p. (in Russian).

Zha Y, Qian Q. Protein Nutrition and Malnutrition in CKD and ESRD. Nutrients. 2017;9(3):208. doi:10.3390/nu9030208.

Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21 Suppl 1(Suppl 1):S21–S27. doi:10.1111/hdi.12556.

Hamano N, Komaba H, Fukagawa M. Magnesium as a new player in CKD: too little is as bad as too much?. Kidney Int. 2017;92(5):1034–1036. doi:10.1016/j.kint.2017.05.032.

Authors/Task Force Members:, Catapano AL, Graham I, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344. doi:10.1016/j.atherosclerosis.2016.08.018.

Coburn JW, Popovtzer MM, Massry SG, Kleeman CR. The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med. 1969;124(3):302–311.

Lin CC, Huang YL. Chromium, zinc and magnesium status in type 1 diabetes. Curr Opin Clin Nutr Metab Care. 2015;18(6):588–592. doi:10.1097/MCO.0000000000000225.

van de Wal-Visscher ER, Kooman JP, van der Sande FM. Magnesium in Chronic Kidney Disease: Should We Care?. Blood Purif. 2018;45(1-3):173–178. doi:10.1159/000485212.

Ladenson PW, author. Diagnosis of Hypothyroidism. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s The Thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. 912 p.

Carrero JJ, Stenvinkel P, Lindholm B, authors. Endocrine Aspects of Chronic Kidney Disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Brenner BM, eds. Brenner and Rector's The Kidney E-Book. 9th ed. Philadelphia: Elsevier Saunders; 2011. 21224-2137 pp.

Wiersinga WM, van den Berghe G, authors. Nonthyroidal Illness Syndrome. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s The Thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. 912 p.

Esfandiari NH, Papaleontiou M. Biochemical Testing in Thyroid Disorders. Endocrinol Metab Clin North Am. 2017;46(3):631–648. doi:10.1016/j.ecl.2017.04.002.

Pankiv VI, Yuzvenko TYu, Pankiv IV. Type 2 diabetes mellitus and subclinical hypothyroidism: focusing on the role of cholecalciferol. Problems of endocrine pathology. 2019;2:46-51. doi:10.21856/j-PEP.2019.2.07.

Downloads

Published

2020-02-01

Issue

Vol. 16 No. 1 (2020)

Section

Original Researches

License

Copyright (c) 2020 A.G. Sazonоva, T.V. Mokhort, N.V. Karlovich, V.S. Snapkov, O.E. Valovik, O.V. Ilinchik

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.